Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
This article from Zacks Investment Research suggests that OptimizeRx (OPRX) and Progress Software (PRGS) may currently be undervalued. Utilizing the Zacks Rank system and specific valuation metrics like PEG and P/B ratios, the analysis highlights OPRX's "Strong Buy" rank and "A" grade for Value, alongside favorable comparisons to industry averages. It concludes that both stocks stand out as strong value options based on their earnings outlook and valuation.
OPRX Should I Buy
This article analyzes OptimizeRx Corp (OPRX), concluding it's not a strong buy for long-term beginner investors due to significant headwinds like reduced revenue guidance, weak financial performance, and bearish technical indicators. Despite some positive catalysts such as AI opportunities, the company faces declining profitability and growth, leading to a "hold" recommendation. Analysts have lowered price targets, maintaining a "Buy" rating with caution.
OptimizeRx (OPRX) price target decreased by 40.41% to 14.79
This article reports a significant decrease in OptimizeRx (OPRX)'s price target, which has been lowered by 40.41% to $14.79. The content provided is minimal, originating from MSN, and lacks further details regarding the reasons for this price target adjustment.
Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
This article evaluates OptimizeRx (OPRX) and Progress Software (PRGS) as potentially undervalued stocks for investors. It highlights OPRX's Zacks Rank #1 (Strong Buy) and "A" grade for Value, citing its PEG ratio of 0.96 and P/B ratio of 2.83, both favorable compared to its industry. Similarly, PRGS is noted with a Zacks Rank #2 (Buy) and "A" grade for Value, showcasing its attractive P/E, PEG, and P/B ratios.
OptimizeRx (NASDAQ: OPRX) switches auditors from UHY LLP to Grant Thornton
OptimizeRx (NASDAQ: OPRX) has announced a change in its independent auditor, dismissing UHY LLP and appointing Grant Thornton LLP for the fiscal year ending December 31, 2026. UHY's audit reports for 2024 and 2025 were unqualified, meaning there were no adverse opinions or disagreements, despite a previously disclosed material weakness in internal control over financial reporting related to third-party data. This change appears to be a standard transition as there were no disagreements or reportable events between OptimizeRx and UHY.
OptimizeRx (OPRX) soars 5.9%: Is further upside left in the stock?
The article reports that OptimizeRx (OPRX) stock increased by 5.9%, leading to a discussion on whether the stock has potential for further growth. Investors are encouraged to examine recent price changes, business fundamentals, and analyst forecasts to determine future performance.
OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
OptimizeRx Corp. (NASDAQ:OPRX) has received a "Moderate Buy" consensus recommendation from nine analysts, with an average one-year price target of $17.57. The company's stock opened at $6.60 and has a twelve-month high of $22.25, with several brokers recently trimming their price targets. OptimizeRx has also initiated a $10.0 million share repurchase program, and institutional investors own approximately 76.5% of the stock.
Vanguard disaggregates holdings; OPRX parent reports 0 shares (OPRX)
The Vanguard Group filed a Schedule 13G/A for OptimizeRx Corp (OPRX) reporting zero beneficial ownership due to an internal realignment effective January 12, 2026. This realignment means certain Vanguard subsidiaries will now report their holdings separately. The filing clarifies that this is a reporting change, not a sale of OPRX shares.
OPRX Technical Analysis & ETF Price Forecast
The article provides a technical analysis of OptimizeRx Corp (OPRX), indicating a "Neutral" overall sentiment based on various technical indicators. While the MACD suggests a Neutral stance, several moving averages (5-Day, 10-Day, 20-Day, 60-Day, 200-Day, 250-Day) show a "Buy" signal given the current share price of $6.6. Momentum indicators like RSI, Stochastic Oscillator, and CCI are also analyzed but show a neutral or undefined outlook.
OptimizeRx (OPRX) Jumps 5.9%: Does the Stock Have More Room to Grow?
OptimizeRx (OPRX) saw its stock jump 5.9% to $7.18 due to an expanding market presence, robust business strategy, and strong demand for its Dynamic Audience Activation Platform (DAAP). The company anticipates AI to be a growth catalyst and projects 2026 revenues between $109 million and $114 million, with adjusted EBITDA between $21 million and $25 million. Despite a "Strong Buy" Zacks Rank, investors are advised to monitor the stock closely due to recent downward revisions in quarterly earnings estimates.
OptimizeRx (OPRX) Jumps 5.9%: Does the Stock Have More Room to Grow?
OptimizeRx (OPRX) saw its stock jump 5.9% to $7.18, driven by its expanding market presence, robust business strategy, and the successful adoption of its Dynamic Audience Activation Platform. Despite a significant year-over-year earnings decrease forecasted, the company's strategic initiatives, including a share repurchase program and a positive outlook on AI's role, suggest potential for continued growth. Analysts' downward revisions on future EPS, however, warrant close monitoring by investors.
OPRX SEC Filings - Optimizerx Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Optimizerx (OPRX) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports, along with insider trading forms. It highlights recent filings detailing leadership changes, quarterly financial results showing strong revenue growth, and insider stock awards. The platform also offers AI-powered summaries to help investors understand these documents.
Earnings call transcript: OptimizeRx Q4 2025 earnings beat forecasts, stock dips
OptimizeRx (OPRX) reported strong financial results for Q4 2025, with EPS of $0.51 and revenue of $32.2 million, both exceeding forecasts. Despite the earnings beat and a record gross margin of 74.8%, the stock declined 14.36% in after-hours trading, potentially due to broader market conditions or investor concerns about future normalized margins. The company provided 2026 guidance with revenue between $109 million-$114 million and adjusted EBITDA between $21 million-$25 million, reflecting a more conservative view on revenue due to market shifts and client spending adjustments.
OptimizeRx (OPRX) Jumps 5.9%: Does the Stock Have More Room to Grow?
OptimizeRx (OPRX) shares rose 5.9% due to its expanding market presence and strong business strategy, driven by its Dynamic Audience Activation Platform and new customer acquisition, particularly among mid-sized life sciences companies. The company views AI as a growth catalyst, expecting it to free up marketing resources, and projects 2026 revenues between $109 million and $114 million with adjusted EBITDA of $21 million to $25 million. Despite positive strategic outlooks and a "Strong Buy" Zacks Rank, upcoming quarterly earnings are expected to decrease significantly, and negative revisions to EPS estimates suggest investors should closely monitor the stock's ability to sustain its rally.
Best Value Stocks to Buy for March 24th
This article identifies three top-ranked value stocks to consider: OptimizeRx (OPRX), Mercury General (MCY), and Strategic Education (STRA). These companies are highlighted for their strong value characteristics, including favorable P/E ratios compared to their industries and recent positive revisions in analyst earnings estimates.
Best Value Stocks to Buy for March 24th
This article identifies three value stocks recommended by Zacks Investment Research for March 24th: OptimizeRx (OPRX), Mercury General (MCY), and Strategic Education (STRA). Each stock holds a Zacks Rank #1 (Strong Buy) and demonstrates strong value characteristics, including favorable price-to-earnings ratios compared to their respective industries and A or B Value Scores. The current year earnings estimates for all three companies have shown recent increases.
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) has reported strong financial results for the second quarter, surpassing both earnings and revenue estimates. The company achieved an adjusted EPS of $0.07, significantly better than the expected $0.01, and revenue reached $18.3 million, exceeding the analysts' consensus of $17.63 million. This positive performance is attributed to the expansion of its client base and increased utilization of its digital health platform by pharmaceutical companies.
If You Invested $1,000 in Optimizerx Corp (OPRX)
This article analyzes the historical performance of investing $1,000 in Optimizerx Corp (OPRX) over one, five, and ten years. It reveals that a $1,000 investment made 10 years ago would now be worth $2,102, while investments made more recently have seen significant losses. The article also provides an overview of Optimizerx Corp, detailing its business model, platform capabilities, market orientation, and corporate structure.
OPRX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for OptimizeRx Corp (OPRX), indicating a "Strong Sell" consensus based on various technical indicators and moving averages as of March 20, 2026. The stock is trading below both its 60-day and 200-day moving averages, with key support at $5.862 and resistance at $6.994. Momentum indicators like MACD also signal a sell, while RSI suggests a neutral condition.
OptimizeRx Corp. (NASDAQ:OPRX) Short Interest Down 16.4% in February
OptimizeRx Corp. (NASDAQ: OPRX) experienced a 16.4% decrease in short interest during February, with 1,398,242 shares shorted, representing 7.9% of the stock. The company's board also authorized a $10 million stock buyback program, indicating a belief that the stock may be undervalued. Analyst ratings for OPRX are mixed, with a consensus of "Moderate Buy" but varied price targets.
OptimizeRx (OPRX) outlines AI-driven pharma marketing strategy and key risks
OptimizeRx (OPRX) has outlined its AI-driven pharmaceutical marketing strategy, leveraging its Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) solutions to deliver targeted campaigns to healthcare providers and consumers. The company's annual report, a Form 10-K, also details significant risks, including customer concentration, regulatory challenges in healthcare advertising and data privacy, cybersecurity threats, and the financial covenants associated with its $40 million term loan. OptimizeRx aims to balance growth with profitability and transition towards a subscription-based revenue model for its data offerings.
Should you sell your OptimizeRx stock?
Roth Capital Markets analyst Richard Baldry maintained a "Buy" rating on OptimizeRx (NASDAQ: OPRX) despite lowering its 12-month price target to $18.00. While Q4 2025 revenue was flat year-over-year due to pharmaceutical marketing budget headwinds, the company achieved a strong profitability beat with record Adjusted EBITDA and pro forma earnings per share. Baldry predicts continued revenue headwinds in the first half of 2026 but expects profitability to persist, indicating a stable outlook for the stock.
OptimizeRx Corporation Common Stock OPRX ) Stock Price Today & Analysis
This article provides an analysis of OptimizeRx Corporation (OPRX) stock, including its current price, fundamental financials, and company overview. It also offers FAQs for potential investors on how to buy OPRX stock through the Gotrade app, minimum investment, dividend policy, market hours, and valuation methods. OptimizeRx is highlighted as a digital health messaging company facilitating communication between pharmaceutical companies, healthcare providers, and patients.
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
OptimizeRx announced strong financial results for Q4 and the full year 2025, with Q4 revenue of $32.2 million, a 9% increase in gross profit, and record net income and adjusted EBITDA. The company also provided updated 2026 revenue guidance of $109-$114 million and adjusted EBITDA guidance of $21-$25 million, and authorized a $10 million share repurchase program. Despite potential near-term market volatility due to MFN pricing, OptimizeRx remains confident in its business model and the critical role it plays in connecting life sciences companies with healthcare professionals and patients.
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ: OPRX) reported strong Q4 and full-year 2025 results, exceeding consensus estimates with Q4 revenue of $32.2 million and adjusted EBITDA of $12 million. Despite this, the company updated its 2026 guidance to a more conservative revenue range of $109 million to $114 million and adjusted EBITDA of $21 million to $25 million due to a market shift away from managed services and client conservatism driven by MFN pricing. OptimizeRx leadership expressed confidence in long-term value creation, highlighted by a $10 million share repurchase program and the view that AI will be a tailwind, not a disruption, for their business model.
Stephens cuts OptimizeRx stock price target on soft pharma budgets
Stephens has lowered its price target for OptimizeRx Corporation (NASDAQ: OPRX) to $10.00 from $17.00, citing soft pharmaceutical marketing budgets, despite a recent revenue beat and improved gross margins. The company also reduced its fiscal 2026 revenue guidance by 8%. Despite the near-term challenges, Stephens remains patient, expecting a potential budget rebound in the latter half of 2026, while InvestingPro analysis suggests the stock is currently undervalued with good financial health.
OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty
OptimizeRx (OPRX) shares fell due to market volatility and uncertainty surrounding Most Favored Nation (MFN) pricing, despite beating Q4 earnings expectations. The company issued lower 2026 revenue guidance, reflecting cautious customer spending. CEO Stephen Silvestro noted solid engagement but acknowledged near-term headwinds, anticipating AI advancements to shift marketing dollars toward areas where OptimizeRx provides value.
OptimizeRx (OPRX) Target Price Lowered by Stephens & Co. | OPRX Stock News
Stephens & Co. analyst Jeff Garro has lowered the price target for OptimizeRx (OPRX) from $17.00 to $10.00, representing a 41.18% decrease, while maintaining an "Equal-Weight" rating. This adjustment reflects a cautious sentiment among analysts, despite other firms like Citizens and JMP Securities having previously increased their price targets for OPRX. OptimizeRx, which provides digital health messaging via electronic health records, has an average target price of $20.83 from 6 analysts, suggesting a significant upside from its current price, and a consensus "Outperform" recommendation from 7 brokerage firms.
OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty
OptimizeRx (NASDAQ: OPRX) shares are experiencing volatility due to uncertainty surrounding Most Favored Nation (MFN) pricing, despite reporting better-than-expected Q4 earnings. The company has revised its 2026 revenue and adjusted EBITDA guidance downwards because of cautious customer spending. Technical analysis indicates a bearish trend, with the stock trading below its 20-day and 100-day SMAs, though analyst ratings still show a "Buy" consensus.
Stephens cuts OptimizeRx stock price target on soft pharma budgets
Stephens has lowered its price target for OptimizeRx Corporation (NASDAQ:OPRX) to $10.00 from $17.00, citing softer pharmaceutical marketing budgets despite strong Q4 2025 earnings. While the company's revenue and gross margins improved, a reduction in the fiscal 2026 revenue guidance by 8% led to the price target adjustment. OptimizeRx expects increased budget allocation in the latter half of 2026, and its stock is considered undervalued by InvestingPro analysis.
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
OptimizeRx Corporation reported strong financial results for Q4 and full year 2025, with full-year revenue increasing 19% to $109.4 million and adjusted EBITDA reaching $24.3 million. The company announced a $10 million share repurchase program and updated its fiscal year 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million. OptimizeRx also highlighted its achievement of the "Rule of 40" benchmark, demonstrating profitable growth, and its continued focus on integrating AI to enhance its healthcare technology solutions.
OptimizeRx (OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx (OPRX) reported strong Q4 and full-year 2025 financial results, with double-digit revenue growth and a more than doubling of adjusted EBITDA and operating cash flow year over year. The company is actively shifting towards subscription-based Dynamic Audience Activation Platform (DAP) revenues and expanding its client base in mid-tier and long-tail life sciences. Despite a strong performance, OptimizeRx anticipates a slower start to 2026 due to market shifts away from managed services and client conservatism related to most-favored nation pricing negotiations, leading to a revised, more conservative revenue guidance for the year while maintaining a focus on profitability.
From loss to profit: OptimizeRx posts record $109.4M sales and $10M buyback
OptimizeRx (OPRX) reported strong financial results for Q4 and full-year 2025, with record full-year revenue of $109.4 million and a significant improvement from a net loss to a net income of $5.1 million. The company announced a $10 million share repurchase program and provided 2026 revenue guidance between $109 million and $114 million. Despite potential near-term headwinds from market volatility and MFN pricing uncertainty, OptimizeRx emphasized its continued leadership in healthcare technology and its achievement of the "Rule of 40" benchmark for profitable growth.
OptimizeRx (OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx (OPRX) reported strong Q4 and full-year 2025 results with significant growth in revenue, adjusted EBITDA, and operating cash flow, driven by product mix improvements and cost optimization. Despite near-term softness in contracted revenue due to market shifts away from managed services and client conservatism around "most favored nation" pricing negotiations, the company remains confident in long-term value creation and authorized a $10 million share repurchase program. OptimizeRx emphasized its strategic focus on expanding subscription-based DAP revenues and targeting mid-tier life sciences clients, leveraging AI as a potential tailwind for future growth.
OptimizeRx Authorizes $10 Million Share Repurchase Program
OptimizeRx recently amended its financing agreement to extend debt maturity and allow for a $10 million share repurchase program, which was formally authorized on March 5, 2026. This move, signaling confidence in the company's financial health, follows a strong 2025 with 19% revenue growth and a swing to GAAP profitability. Despite near-term demand headwinds in life sciences spending, the company has updated its 2026 guidance, projecting sustained profitability.
Optimizerx Corp Enters Amendment No. 4 To Financing Agreement- SEC Filing
Optimizerx Corp has entered into Amendment No. 4 to its financing agreement, as disclosed in an SEC filing. This brief announcement, reported by Refinitiv via Reuters, indicates a change or update to the company's existing financial arrangements.
OptimizeRx Corporation (OPRX) Stock Rises on Q4 2025 Earnings
OptimizeRx Corporation (OPRX) reported a strong Q4 2025, with revenue slightly above estimates and a significant increase in operating profit and cash flow. Diluted EPS also surpassed expectations, leading to a 14.5% rise in stock price after market close. Insider trading saw sales by top executives, while institutional investors showed mixed activity, with some significant additions and removals of shares. Analyst ratings remain positive, with "Market Outperform" ratings and a median price target of $23.0.
OptimizeRx (Nasdaq: OPRX) returns to profit and unveils $10M share repurchase plan
OptimizeRx (OPRX) reported a return to profitability in 2025 with $5.1 million in GAAP net income and a 19% revenue increase to $109.4 million. The company also announced a new $10 million share repurchase program and extended its term loan maturity. For 2026, OptimizeRx provides guidance of $109-$114 million in revenue and $21-$25 million in Adjusted EBITDA.
Earnings To Watch: OptimizeRx Corp (OPRX) Reports Q4 2025 Result
OptimizeRx Corp (OPRX) is slated to release its Q4 2025 earnings on March 5, 2026, with revenue estimated at $31.10 million and earnings per share at $0.09. Analysts forecast full-year 2025 revenue at $108.18 million and earnings at $0.05 per share. The average target price from six analysts is $24.33, implying a significant upside from the current price.
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of "Moderate Buy" by Analysts
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $20.50, significantly above its current trading price of $7.32. Institutional investors hold 76.47% of the company, and several, including Vanguard and Royce & Associates, have recently increased their positions. Despite some analyst downgrades, the majority maintain a positive outlook, highlighting the company's valuation gap and strategic position in digital healthcare.
OptimizeRx Corp expected to post earnings of 23 cents a share - Earnings Preview
OptimizeRx Corp (OPRX) is expected to announce earnings of 23 cents per share. This information comes from a Reuters earnings preview. The article is a brief financial news piece indicating analyst expectations for the company's performance.
CenterBook Partners LP Invests $6.33 Million in OptimizeRx Corp. $OPRX
CenterBook Partners LP has invested $6.33 million in OptimizeRx Corp. (NASDAQ:OPRX) by acquiring 308,809 shares, representing a 1.66% stake. Institutional interest in OptimizeRx is growing, with Vanguard and Manatuck Hill Partners also increasing their positions. Despite mixed analyst ratings, the consensus remains a "Moderate Buy" with an average price target of $20.50.
OptimizeRx (OPRX): Small-Cap AI Health Stock Quietly Repricing Higher
OptimizeRx (OPRX), a small-cap digital health company, is experiencing a quiet rebound driven by improving revenue trends, narrowing losses, and increased investor interest in AI-enabled healthcare. The company's strategic positioning within EHR and e-prescribing workflows for pharma messaging and data analytics, combined with a recovering small-cap risk appetite, is attracting attention despite inherent volatility. Investors are weighing its potential as a growth play in digital health against risks like client concentration and execution on AI products.
OptimizeRx (OPRX): Small-Cap AI Health Stock Quietly Repricing Higher
OptimizeRx (OPRX), a small-cap digital health company, is experiencing a rebound due to improved revenue trends, narrowing losses, and increased investor interest in AI-enabled healthcare. The company's focus on profitability, AI exposure through its digital pharma engagement platform, and recovery in small-cap risk appetite are driving this rerating. Investors are evaluating whether this is a temporary bounce or the start of a sustained growth period, given its niche competitive positioning and the evolving US healthcare digitalization landscape.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
OptimizeRx will host a conference call on March 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The company will issue a press release with the financial results prior to the call. A replay of the call will be available for 12 months on the OptimizeRx website.
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Analysts
OptimizeRx Corp. (NASDAQ:OPRX) has received a consensus "Moderate Buy" rating from analysts, with an average 1-year price target of $21.00. The company recently reported strong quarterly earnings, beating EPS and revenue estimates, but analysts still project a negative EPS for the current fiscal year. Institutional investors hold a significant portion of the stock, which has seen some modifications in holdings by various firms.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial
OptimizeRx Corporation (Nasdaq: OPRX) has announced a conference call to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The call is scheduled for March 5, 2026, at 4:30 p.m. Eastern Time. Financial results will be released via press release prior to the call, which will include a Q&A session with OptimizeRx management.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial
OptimizeRx will hold a conference call on March 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter period ended December 31, 2025. The company specializes in healthcare technology solutions, utilizing AI-driven tools to connect life sciences brands with healthcare professionals and patients. A replay of the call will be available for 12 months on the investor relations section of their website.
Strength Seen in OptimizeRx (OPRX): Can Its 7.5% Jump Turn into More Strength?
OptimizeRx (OPRX) shares jumped 7.5% after the last trading session, driven by optimism regarding its operational execution in the digital pharma market, strong contracted revenue growth, and effective cross-selling strategies. The company raised its 2025 revenue guidance to $105-$109 million, but its reliance on the pharma market makes it susceptible to sector spending cycles. Upcoming quarterly earnings are projected at $0.23 per share, a 23.3% year-over-year decrease, with revenues expected to be down 2.3% to $31.58 million.
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
OptimizeRx Corporation will host a conference call on Thursday, March 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The company specializes in healthcare technology solutions, utilizing AI-driven tools to connect life sciences companies with healthcare professionals and patients. Financial results will be released via press release prior to the call, which will also include a question-and-answer session.
